An NSAID formulated to penetrate target ocular tissues
PROLENSA
®
POWERED FOR PENETRATION
Available in a 3-mL bottle size
Please see brief summary of Prescribing Information on adjacent page.
References: 1. PROLENSA
®
Prescribing Information, April 2013. 2. Data on file, Bausch & Lomb Incorporated. 3. Baklayan GA, Patterson HM,
Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of 14C-labeled bromfenac following topical instillation into the
eyes of New Zealand White rabbits.
J Ocul Pharmacol Ther. 2008;24(4):392-398. 4. BROMDAY
®
Prescribing Information, October 2012.
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
© 2015 Bausch & Lomb Incorporated. All rights reserved. Printed in USA. US/PRA/15/0015
PROLENSA
®
delivers potency and corneal penetration
with QD efficacy
1,2
•
Advanced formulation delivers corneal penetration
1-3
•
Proven efficacy at a low concentration
1,4
INDICATIONS AND USAGE
PROLENSA
®
(bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti‑inflammatory drug (NSAID)
indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who
have undergone cataract surgery.
IMPORTANT SAFETY INFORMATION ABOUT PROLENSA
®
Warnings and Precautions
• Sulfite allergic reactions
• Slow or delayed healing
• Potential for cross‑sensitivity
• Increased bleeding of ocular tissues
• Corneal effects, including keratitis
• Contact lens wear
Adverse Reactions
The most commonly reported adverse reactions
in 3%‑8% of patients were anterior chamber
inflammation, foreign body sensation, eye pain,
photophobia, and blurred vision.
